[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591517":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":36,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Resected GEP-NETs",null,"Surgery for resection of NETs, including complete resection and cytoreduction resection, as advised by the treating physician. The extent and timing of surgery is determined by the treating physician.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jessica Armah, MSc","CONTACT","416-480-6100","jessica.armah@sri.utoronto.ca",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Toronto","Ontario","M4N 3M5","Canada","CA",{"type":27,"coordinates":28},"Point",[29,30],-79.39864,43.70643,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":35},"Julie Hallet, MD MSc FRCSC FSSO","julie.hallet@sunnybrook.ca",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dr. Julie Hallet","Associate Scientist","100591517","life-following-excision-of-neuroendocrine-tumors-100591517",false,"NCT06981455","Life Following Excision of Neuroendocrine Tumors","LIFE-NETs (Life Following Excision of Neuroendocrine Tumors): a Multi-institutional Prospective Observational Cohort Study of Quality of Life After Surgery for Neuroendocrine Tumors","LIFENETS","Inclusion Criteria:\n\n* Age \\>18 years old\n* Diagnosis of well-differentiated grade 1 to 3 NETs via histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on SSTR-PET scan).\n* Consents to surgery for resection of localized, loco-regional, or metastatic gastro-enteric (midgut) and pancreatic neuroendocrine tumor (GEP-NET).\n\nExclusion Criteria:\n\n* Pre-operative diagnosis of neuroendocrine carcinoma on histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on FDG-PET scan and no avidity on SSTR-PET scan).\n* Declines surgery.\n* Unable to respond to study questionnaires (not proficient in local language).","ALL","18 Years",{"count":51,"type":52},246,"ESTIMATED","OBSERVATIONAL","Neuroendocrine tumors (NETs), often seen as \"chronic cancer\" present a survival paradox with relatively prolonged patient survival despite active disease. Treatment strategies emphasize management over cure, integrating tumor control with quality of life (QOL) considerations. Surgery is a cornerstone of NET management but demands a careful balance between its potential benefits and the morbidity risks. Current literature on post-surgical QOL is limited and non-generalizable, underscoring the need for comprehensive, multi-institutional data to inform surgical decisions.\n\nWe will study QOL after surgery for NETs in a prospective multi-institutional international cohort study. Specifically, we aim to 1) describe the post-operative QOL of patients with NETs and 2) identify factors associated with QOL measures after surgery for NETs. This project will be led in partnership by the Susan Leslie Clinic for NETs at Sunnybrook Health Sciences Centre in Toronto, Canada, and the IRCCS San Raffaele ENETS Centre of Excellent in Milan, Italy, and enrol adults undergoing surgery for resection of gastro-entero-pancreatic NETs across 12 North-American and European high-volume NETs surgery centres over a 18-month period. Measures of QOL using the SF-12 Survey, the EORTC-QLQ C30 and GEPNET21 tool, and clinical symptoms assessment, will be captured prior to surgery and at 6, 12, 24, and 36 months after surgery. Mixed linear regression models with random intercepts to account for longitudinal data correlation and individual variability will be used to analyze the QOL measures over time. Patient and service users engagement (PSUE) will be integrated throughout the study continuum.\n\nThis project will fill the knowledge gap in QOL after surgery for NETs, with a view to support better-informed surgical decisions and patient-centred care. The prospective, multi-institutional, and international design promises a comprehensive understanding of the impact of surgery on patient's lives, potentially shaping management pathways globally.",[56,57],"Neuroendocrine (NE) Tumors","Neuroendocrine Tumor GEP Grade 1-3",[59,60,61,62],"surgery","quality of life","carcinoid","neuroendocrine","2025-05-13",{"date":65,"type":66},"2025-05-20","ACTUAL",{"date":68,"type":66},"2025-04-28",{"date":70,"type":52},"2028-12-31",{"name":5,"class":6},1]